Sample size calculation for active-arm trial with counterfactual incidence based on recency assay

@article{Gao2021SampleSC,
  title={Sample size calculation for active-arm trial with counterfactual incidence based on recency assay},
  author={Fei Gao and David V. Glidden and James P Hughes and Deborah J Donnell},
  journal={Statistical Communications in Infectious Diseases},
  year={2021},
  volume={13}
}
Abstract Objectives The past decade has seen tremendous progress in the development of biomedical agents that are effective as pre-exposure prophylaxis (PrEP) for HIV prevention. To expand the choice of products and delivery methods, new medications and delivery methods are under development. Future trials of non-inferiority, given the high efficacy of ARV-based PrEP products as they become current or future standard of care, would require a large number of participants and long follow-up time… 

Figures and Tables from this paper

Statistical considerations for cross‐sectional HIV incidence estimation based on recency test
TLDR
A theoretical framework is presented with which to understand and assess the performance of two commonly used estimators of HIV incidence estimation under realistic HIV epidemiological dynamics and it is found that the snapshot estimator and the adjusted estimator perform well when their corresponding assumptions hold.
Testing for Treatment Effect Twice Using Internal and External Controls in Clinical Trials
TLDR
A sensitivity analysis approach is proposed to quantify the magnitude of bias from unmeasured covariates that would need to be present to alter the study conclusion that presumed no unme measured biases are introduced by employing external controls.
Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
TLDR
The well‐characterized adherence‐efficacy relationship for F/TDF was used to back‐calculate the (non‐PrEP) counterfactual background HIV incidence (bHIV) in a randomized trial of a novel PrEP agent and estimate comparative efficacy (to counterfactUAL bHIV).

References

SHOWING 1-10 OF 16 REFERENCES
Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.
  • D. Glidden
  • Biology
    Current opinion in HIV and AIDS
  • 2019
TLDR
The development of new long-acting PrEP regimens can be accelerated by innovations in design, ingenuity in synthesizing data sources, and application of causal inference methods.
Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review
TLDR
A narrative review seeks to identify individual and systemic barriers to PrEP usage in the USA and uncovered a complex array of structural, social, clinical, and behavioral barriers, including knowledge/awareness of PrEP, perception of HIV risk, stigma from healthcare providers or family/partners/friends, distrust of healthcare providers/systems, access toPrEP, costs of Pr EP, and concerns around PrEP side effects/medication interactions.
Snapshot Estimators of Recent HIV Incidence Rates
TLDR
This work proposes a method for estimating recent HIV incidence in a population via a single sample at a single point in time and relies on understanding the progression of certain markers such as CD4 counts following infection.
Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating
TLDR
An improved and more general framework for estimating the duration of HIV infection by interpreting any combination of diagnostic test results, whether obtained on single or multiple days, into an estimated date of detectable infection, or EDDI.
Adaptive non-inferiority margins under observable non-constancy
TLDR
A pre-specified method is described, using baseline characteristics or post-baseline predictors in the active-control arm, to adapt the non-inferiority margin at the end of the study if constancy is violated, to help adjust for constancy violations that will inevitably occur in real clinical trials.
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.
TLDR
Several key elements of the effort to expand PrEP uptake for at-risk populations who would benefit most are considered, such as increasing access to PrEP, integrating PrEP programs with other services, promoting PrEP persistence and developing systems for monitoring PrEP use.
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
TLDR
Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown.
Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
TLDR
A novel method to compute the rate of new HIV diagnoses at the Metropolitan Statistical Area (MSA) level in the US to support the evaluation of comprehensive treatment and prevention efforts over time is proposed.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
TLDR
Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women, and both study medications significantly reduced the HIV- 1 incidence among both men andWomen.
...
...